FY2018 EPS Estimates for Aquinox Pharmaceuticals Lifted by Analyst (AQXP)

Aquinox Pharmaceuticals (NASDAQ:AQXP) – Investment analysts at Cantor Fitzgerald lifted their FY2018 earnings per share estimates for shares of Aquinox Pharmaceuticals in a research note issued to investors on Tuesday, May 22nd. Cantor Fitzgerald analyst W. Tanner now expects that the company will earn ($2.24) per share for the year, up from their prior estimate of ($2.27). Cantor Fitzgerald currently has a “Buy” rating and a $28.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aquinox Pharmaceuticals’ FY2019 earnings at ($1.64) EPS.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Tuesday, May 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.08.

A number of other research analysts have also recently issued reports on AQXP. BidaskClub raised Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Guggenheim started coverage on Aquinox Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $26.00 target price for the company. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 16th. ValuEngine raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Tuesday, May 8th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aquinox Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $22.80.

Aquinox Pharmaceuticals opened at $12.56 on Thursday, Marketbeat.com reports. Aquinox Pharmaceuticals has a 1 year low of $10.02 and a 1 year high of $16.90. The stock has a market capitalization of $290.80 million, a price-to-earnings ratio of -5.87 and a beta of -14.25.

In other news, Director Daniel J. Levitt sold 3,906 shares of the company’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $12.67, for a total transaction of $49,489.02. Following the completion of the transaction, the director now directly owns 3,906 shares of the company’s stock, valued at $49,489.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.70% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Emory University boosted its position in shares of Aquinox Pharmaceuticals by 38.3% during the fourth quarter. Emory University now owns 170,404 shares of the company’s stock worth $2,004,000 after buying an additional 47,154 shares during the period. Millennium Management LLC boosted its position in shares of Aquinox Pharmaceuticals by 548.4% during the fourth quarter. Millennium Management LLC now owns 138,132 shares of the company’s stock worth $1,624,000 after buying an additional 116,830 shares during the period. Franklin Resources Inc. raised its holdings in Aquinox Pharmaceuticals by 1.1% during the fourth quarter. Franklin Resources Inc. now owns 1,334,607 shares of the company’s stock worth $15,695,000 after acquiring an additional 14,362 shares in the last quarter. University of Notre Dame DU Lac raised its holdings in Aquinox Pharmaceuticals by 32.0% during the fourth quarter. University of Notre Dame DU Lac now owns 251,091 shares of the company’s stock worth $2,953,000 after acquiring an additional 60,808 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in Aquinox Pharmaceuticals during the fourth quarter worth about $476,000. 90.05% of the stock is owned by institutional investors.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply